Differentially expressed genes between high-risk human papillomavirus types in human cervical cancer cells

International Journal of Gynecological Cancer

Volumn 17, Issue 2, 2007, Pages 484-491

  Vazquez Ortiz, G ^a   Garcia J A ^b   Ciudad, C J ^c   Noe V ^c   Penuelas S ^c   Lopez Romero R ^a   Mendoza Lorenzo, P ^a   Pina Sanchez P ^a   Salcedo, M ^a,d  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b KECK GRADUATE INSTITUTE   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Cervical cancer; Differential expression; HPV

Indexed keywords

ABC TRANSPORTER; ACTIVATING TRANSCRIPTION FACTOR 7; CHROMOSOME 20 OPEN READING FRAME; COMPLEMENTARY DNA; CYCLIN C; DEATH EFFECTOR DOMAIN CONTAINING PROTEIN; PROTEIN; RETICULOCALBIN 2; SOLUTE CARRIER FAMILY 5 MEMBER 12; SPERM ASSOCIATED ANTIGEN 8; SUPPRESSOR OF VARIEGATION 3 9 HOMOLOG 1; SURVIVIN; TRANSCRIPTION FACTOR 5; UBIQUITINATION FACTOR E4A; UNCLASSIFIED DRUG; WAS PROTEIN FAMILY MEMBER 3;

ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; VIRUS GENE;

CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA PROBES, HPV; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 33947246003     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00831.x     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
3. Munoz N, Kato I, Bosch FX et al. Cervical cancer and herpes simplex virus type 2: case-control studies in Spain and Colombia, with special reference to immunoglobulin-G sub-classes. Int J Cancer 1995;60:438-42.
4. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
5. Pina-Sanchez P, Hernandez-Hernandez D, Lopez-Romero R, Vazquez-Ortiz G, Salcedo M. Human papillomavirus-specific viral types are common in Mexican women affected by cervical lesions. Int J Gynecol Cancer 2006;16:1-7.
6. Barnes W, Woodworth G, Waggoner S et al. Rapid dysplastic transformation of human genital cells by human papillomavirus type 18. Gynecol Oncol 1990;38:343-6.
7. Im SS, Wilczynski SP, Burger RA, Monk BJ. Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res 2003;9:4145-50.
8. Barnes W, Delgado G, Kurman RJ et al. Possible prognostic significance of human papillomavirus type in cervical cancer. Gynecol Oncol 1988;29:267-73.
9. Walker J, Bloss JD, Liao SY, Berman M, Bergen S, Wilczynski SP. Human papillomavirus genotype as a prognostic indicator in carcinoma of the uterine cervix. Obstet Gynecol 1989;74:781-5.
10. Burger RA, Monk BJ, Kurosaki T et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996;88:1361-8.
11. Lombard I, Vincent-Salomon A, Validire P et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol 1998;16:2613-9.
12. Schwartz SM, Daling JR, Shera KA et al. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol 2001;19:1906-15.
13. Vazquez-Ortiz G, Ciudad CJ, Pina P et al. Gene identification by cDNA arrays in HPV-positive cervical cancer. Arch Med Res 2005;36:448-58.
14. Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K et al. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 2005;5:68.
15. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
16. Chen JJ, Reid CE, Band V, Androphy EJ. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995;269:529-31.
17. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991;10:4129-35.
18. Tong X, Howley PM. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc Natl Acad Sci U S A 1997;94:4412-7.
19. Lee SS, Weiss RS, Javier RT. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997;94:6670-5.
20. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997;94:11612-6.
21. Tong X, Boll W, Kirchhausen T, Howley PM. Interaction of the bovine papillomavirus E6 protein with the clathrin adaptor complex AP-1. J Virol 1998;72:476-82.
22. Liu Z, Brattain MG, Appert H. Differential display of reticulocalbin in the highly invasive cell line, MDA-MB-435, versus the poorly invasive cell line, MCF-7. Biochem Biophys Res Commun 1997;231:283-9.
23. Chen JJ, Hong Y, Rustamzadeh E, Baleja JD, Androphy EJ. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem 1998;273:13537-44.
24. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001;8:83-92.
25. Campisi J. Suppressing cancer: the importance of being senescent. Science 2005;309:886-7.
26. Contino G, Amati F, Pucci S et al. Expression analysis of the gene encoding for the U-box-type ubiquitin ligase UBE4A in human tissues. Gene 2004;328:69-74.
27. Schickling O, Stegh AH, Byrd J, Peter ME. Nuclear localization of DEDD leads to caspase-6 activation through its death effector domain and inhibition of RNA polymerase I dependent transcription. Cell Death Differ 2001;8:1157-68.
28. Zheng L, Schickling O, Peter ME, Lenardo MJ. The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm. J Biol Chem 2001;276:31945-52.
29. Manos M, Ting Y, Wright D, Lewis A, Broker R, Wolinsky S. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7:209-14.
30. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
31. Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
32. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993.
33. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360-72.
34. Branca M, Giorgi C, Santini D et al. Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol 2005;124:113-21.
35. Borbely AA, Murvai M, Szarka K et al. Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 2006;87:287-94.
36. Borbely AA, Murvai M, Konya J et al. Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J Gen Virol 2006;87:287-94.
37. Vandel L, Nicolas E, Vaute O, Ferreira R, it-Si-Ali S, Trouche D. Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol 2001;21:6484-94.
38. Firestein R, Cui X, Huie P, Cleary ML. Set domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila Su(var)3-9. Mol Cell Biol 2000;20:4900-9.
39. Androphy EJ, Schiller JT, Lowy DR. Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science 1985;230:442-5.
40. Das K, Bohl J, Vande Pol SB: Identification of a second transforming function in bovine papillomavirus type 1 E6 and the role of E6 interactions with paxillin, E6BP, and E6AP. J Virol 2000;74:812-6.
41. Lichtig H, Algrisi M, Botzer LE et al. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 2006;350:216-27.
42. Caren H, Holmstrand A, Sjoberg RM, Martinsson T. The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours. Eur J Cancer 2006;42:381-7.
43. Harris CP, Lu XY, Narayan G, Singh B, Murty VV, Rao PH. Comprehensive molecular cytogenetic characterization of cervical cancer cell lines. Genes Chromosomes Cancer 2003;36:233-41.
44. Stegh AH, Schickling O, Ehret A et al. DEDD, a novel death effector domain-containing protein, targeted to the nucleolus. EMBO J 1998;17:5974-86.
45. Sasaki S, Nakamura T, Arakawa H et al. Isolation and characterization of a novel gene, hRFI, preferentially expressed in esophageal cancer. Oncogene 2002;21:5024-30.